Phio Pharmaceuticals PHIO Stock News

Phio Pharmaceuticals Corp (NASDAQ: PHIO) is running for the top in the market this morning, and for good reason. The company announced positive data from in vivo studies surrounding several INTASYL pipeline programs. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

PHIO Stock Runs On Positive Data

In the press release, Phio Pharmaceuticals said that several of its INTASYL pipeline programs have shown strong antitumoral efficacy from in vivo studies. These programs include PH-762, PH-894, and PH-804.

In the release, the company said that the intratumoral delivery of INTASYL compounds inhibited tumor growth. PHIO said that these results were achibed as a result of these compounds inhibiting tumor growth by overcoming the immunosuppressive tumor microenvironment. This was shown by changes in T cell composition and activation.

As a result, the company believes that these pipeline programs come with great promise in the treatment of solid tumors.

The compounds mentioned above were designed to silence the expression of PD-1, BRD4, and TIGIT. These are proteins that are linked to reduced immune cell function in cancer patients.

In the release, the company said that a series of preclinical in vivo studies in tumor models were conducted and resulted in data showing dose-dependent attenuated tumor growth when compared to control groups.

In a statement, Dr. Simon Fricker, VP of Research at PHIO, had the following to offer:

These exciting new data show that INTASYL compounds are able to overcome the immunosuppressive TME by reprogramming T cells in order to inhibit tumor growth. These data support our belief that Phio’s INTASYL technology can be used to develop powerful immunotherapeutics, which can overcome the shortcomings of currently available systemic immunotherapy. We look forward to continuing our development of INTASYL, including the IND enabling studies which are currently ongoing.

This News Is Huge

All in all, the news released this morning is huge for Phio Pharmaceuticals and its investors. First and foremost, there is a long list of INTASYL compounds under development at the company and the data shows that these compounds may be effective in fighting various solid tumor cancers.

Should these treatments hit the clinic, and the data continue to be as positive as the preclinical data is, the company could be sitting on a figurative goldmine. Brain cancer, colon cancer, breast cancer, and others are included in the solid-tumor classification. This is important as these are some of the largest markets in the oncology industry.

Should the company break into any single solid tumor market, it would be a large opportunity. Keep in mind, we’re talking about a company with a market cap around $10 million. All in all, this data makes PHIO stock one that’s worth watching!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.